Review of the run data shows no pcr abnormalities that could affect the result.Additionally, the internal control amplification is robust with a normal ct value of 30.3.This suggests no inhibition of pcr occurred during this run.Investigation of the complaint kit lot did not identify any product issue.Sample to sample variability can occur, including when sample was collected in relation to disease course; how sample was stored prior to testing; and inadequate or variability in sample collection.Thus, sample to sample results may vary.In addition, the differences in the test design between the roche and cepheid tests could affect the reproducibility of the results.(b)(4).
|
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer from the us alleged discrepant results generated for one patient when using the cobas sars-cov-2 & influenza a/b test for use on the cobas liat system compared to the retest result of a new sample on the cepheid instrument.The sample generated a sars-cov-2 not detected result in the initial test on the cobas liat system.The patient was symptomatic and decided to go to the er where a new sample was collected.Testing of this new sample on the cepheid instrument generated a sars-cov-2 positive result.No harm was alleged.
|